Ixazomib 4mg
| Product Overview | |
| Generic Name | Ixazomib 4mg |
| Brand Name(s) | NINLARO® |
| Product Type | Originator Brand |
| Form | 3, Oral hard capsules |
| Strength | 4mg |
| Therapeutic Class | Oral proteasome inhibitor |
| ATC Code | L01XG03 |
| Manufacturing & Regulatory | |
| Manufacturer | Takeda |
| Country | Denmark, USA |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.6314.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 36 months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
Description
Ixazomib is indicated with lenalidomide and dexamethasone for multiple myeloma after at least one prior therapy. It is given orally once weekly on Days 1, 8 and 15 of a 28-day cycle and should not be crushed, chewed or opened.
